Ribo Newsroom

Ribo's globally first-in-class FXI-targeting siRNA drug, vortosiran, received implied approval for a Phase I clinical trial in China, advancing coordinated development across China and Europe and its global multicenter clinical program.

Ozisiran Delivers Sustained Viral and Antigen Suppression in Chronic Hepatitis D - Preliminary Interim Phase IIa Results

Ribo Proposes Share Swap to Acquire a Minority Stake of its Overseas Subsidiary, Advancing Global Integration Strategy

Ribo’s overseas R&D team and investors visited its Kunshan headquarters and Beijing R&D center for in-depth discussions on project advancement and cross-regional collaboration, strengthening R&D collaboration between the Chinese and Swedish teams and jointly advancing the global development of siRNA therapeutics.

Ribo announced the successful submission of a Phase Ⅰ Clinical Trial Application (CTA) in EU for RBD3133, a novel siRNA therapeutic targeting INHBE (inhibin subunit beta E), with overweight and obesity as its intended future therapeutic indications.